Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Linda Harris
ResearcherPublications, citations & collaboration network
Linda Harris is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 65 works, 738 citations, an h-index of 18 and an i10-index of 24.
65
Works
738
Citations
18
h-index
24
i10-index
IDs:OpenAlex
How has Linda Harris's publication output changed over time?
ScholarIQpublication output · 1987–2022
Output grew500% over the shown period — from 1 works in 1987 to 6 in 2022.
1
2
1
6
1987201920212022
What are the most-cited papers on Linda Harris?
ScholarIQmost cited works
Understanding side effects of therapy for myasthenia gravis and their impact on daily life
Elizabeth D. Bacci, Karin S. Coyne, Jiat Ling Poon, Linda Harris, Audra Boscoe
BMC Neurology. 201967 CitationsOPEN ACCESS
Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life
Audra Boscoe, Haichang Xin, Gilbert L’Italien, Linda Harris, Gary Cutter
Journal of Clinical Neuromuscular Disease. 201956 CitationsOPEN ACCESS
Nasofrontal duct: CT in frontal sinus trauma.
Linda Harris, Gary Marano, D McCorkle
S50280174. 198748 Citations
A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis
Linda Harris, Sophie Graham, Sharon MacLachlan, Alex Exuzides, Saiju Jacob
BMC Neurology. 202248 CitationsOPEN ACCESS
Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
Karissa Johnston, Linda Harris, Lauren Powell, Evan Popoff, Vladimir Coric, Gilbert L’Italien, Curtis P. Schreiber
S143427143. 202243 CitationsOPEN ACCESS
Related on ScholarIQ
University at Buffalo, State University of New York
Institution
Understanding side effects of therapy for myasthenia gravis and their impact on daily life
Paper
Impact of Refractory Myasthenia Gravis on Health-Related Quality of Life
Paper
Nasofrontal duct: CT in frontal sinus trauma.
Paper
A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis
Paper
Monthly migraine days, tablet utilization, and quality of life associated with Rimegepant – post hoc results from an open label safety study (BHV3000–201)
Paper